Prolonged overall survival with lenalidomide plus dexamethasone compared with dexamethasone alone in patients with relapsed or refractory multiple myeloma

被引：13
|
作者：
Weber, Donna [1 ]
Knight, Robert [2 ]
Chen, Christine [3 ]
Spencer, Andrew [4 ]
Yu, Zhinuan [2 ]
Zeldis, Jerome [2 ]
Olesnyckyj, Marta [2 ]
Dimopoulos, Meletios [5 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Celgene Corp, Summit, NJ USA
[3] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[4] Alfred Hosp, Dept Gastroenterol, Melbourne, Vic, Australia
[5] Univ Athens, Sch Med, GR-11527 Athens, Greece
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.412.412
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
412
引用
收藏
页码：128A / 128A
页数：1
相关论文
共 50 条
  • [31] ECONOMIC EVALUATION OF CARFILZOMIB plus LENALIDOMIDE plus DEXAMETHASONE (KRD) VS LENALIDOMIDE plus DEXAMETHASONE (RD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (R/RMM)
    Fonseca, R.
    Panjabi, S.
    Campioni, M.
    Giannopoulou, A.
    Benedict, A.
    Houisse, I.
    Aggarwal, S.
    Jakubowiak, A.
    HAEMATOLOGICA, 2016, 101 : 526 - 526
  • [32] Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice
    Jiri Minarik
    Tomas Pika
    Jakub Radocha
    Alexandra Jungova
    Jan Straub
    Tomas Jelinek
    Ludek Pour
    Petr Pavlicek
    Martin Mistrik
    Lucie Brozova
    Petra Krhovska
    Katerina Machalkova
    Pavel Jindra
    Ivan Spicka
    Hana Plonkova
    Martin Stork
    Jaroslav Bacovsky
    Lenka Capkova
    Michal Sykora
    Petr Kessler
    Lukas Stejskal
    Adriana Heindorfer
    Jana Ullrychova
    Tomas Skacel
    Vladimir Maisnar
    Roman Hajek
    BMC Cancer, 21
  • [33] Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma
    Paludo, Jonas
    Mikhael, Joseph R.
    LaPlant, Betsy R.
    Halvorson, Alese E.
    Kumar, Shaji
    Gertz, Morie A.
    Hayman, Suzanne R.
    Buadi, Francis K.
    Dispenzieri, Angela
    Lust, John A.
    Kapoor, Prashant
    Leung, Nelson
    Russell, Stephen J.
    Dingli, David
    Go, Ronald S.
    Lin, Yi
    Gonsalves, Wilson I.
    Fonseca, Rafael
    Bergsagel, P. Leif
    Roy, Vivek
    Sher, Taimur
    Chanan-Khan, Asher A.
    Ailawadhi, Sikander
    Stewart, A. Keith
    Reeder, Craig B.
    Richardson, Paul G.
    Rajkumar, S. Vincent
    Lacy, Martha Q.
    BLOOD, 2017, 130 (10) : 1198 - 1204
  • [34] Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice
    Minarik, Jiri
    Pika, Tomas
    Radocha, Jakub
    Jungova, Alexandra
    Straub, Jan
    Jelinek, Tomas
    Pour, Ludek
    Pavlicek, Petr
    Mistrik, Martin
    Brozova, Lucie
    Krhovska, Petra
    Machalkova, Katerina
    Jindra, Pavel
    Spicka, Ivan
    Plonkova, Hana
    Stork, Martin
    Bacovsky, Jaroslav
    Capkova, Lenka
    Sykora, Michal
    Kessler, Petr
    Stejskal, Lukas
    Heindorfer, Adriana
    Ullrychova, Jana
    Skacel, Tomas
    Maisnar, Vladimir
    Hajek, Roman
    BMC CANCER, 2021, 21 (01)
  • [35] Impact of chromosomal abnormalities on the efficacy of lenalidomide plus dexamethasone treatment in patients with relapsed/refractory multiple myeloma
    Takashi Yoshida
    Masaki Ri
    Haruna Fujinami
    Yoshiko Oshima
    Takuto Tachita
    Yoshiaki Marumo
    Hirokazu Sasaki
    Shiori Kinoshita
    Haruhito Totani
    Tomoko Narita
    Ayako Masaki
    Asahi Ito
    Shigeru Kusumoto
    Takashi Ishida
    Hirokazu Komatsu
    Shinsuke Iida
    International Journal of Hematology, 2019, 110 : 228 - 236
  • [36] Erratum: Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma
    D S Siegel
    P Richardson
    M Dimopoulos
    P Moreau
    C Mitsiades
    D Weber
    J Houp
    C Gause
    S Vuocolo
    J Eid
    T Graef
    K C Anderson
    Blood Cancer Journal, 2014, 4 : e202 - e202
  • [37] Post-authorization safety of lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma in Turkey
    Tuglular, Ayse Tulin Firatli
    Pehlivan, Mustafa
    Sonmez, Mehmet
    Hacioglu, Sibel Kabukcu
    Saydam, Guray
    Ayyildiz, Orhan
    Kaynar, Leylagul
    Demirkan, Fatih
    Beksac, Meral
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S190 - S191
  • [38] Impact of chromosomal abnormalities on the efficacy of lenalidomide plus dexamethasone treatment in patients with relapsed/refractory multiple myeloma
    Yoshida, Takashi
    Ri, Masaki
    Fujinami, Haruna
    Oshima, Yoshiko
    Tachita, Takuto
    Marumo, Yoshiaki
    Sasaki, Hirokazu
    Kinoshita, Shiori
    Totani, Haruhito
    Narita, Tomoko
    Masaki, Ayako
    Ito, Asahi
    Kusumoto, Shigeru
    Ishida, Takashi
    Komatsu, Hirokazu
    Iida, Shinsuke
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 110 (02) : 228 - 236
  • [39] The efficacy and safety of lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma patients with impaired renal function
    Weber, D. M.
    Spencer, A.
    Wang, M.
    Chen, C.
    Attal, M.
    Niesvizky, R.
    Prince, M.
    Yu, Z.
    Knight, R.
    Dimopoulos, M. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [40] The Efficacy and Safety of Lenalidomide Plus Dexamethasone in Relapsed and/or Refractory Multiple Myeloma Patients With Impaired Renal Function
    Dimopoulos, Meletios
    Alegre, Adrian
    Stadtmauer, Edward A.
    Goldschmidt, Hartmut
    Zonder, Jeffrey A.
    de Castro, Carlos M.
    Masliak, Zvenyslava
    Reece, Donna
    Olesnyckyj, Marta
    Yu, Zhinuan
    Weber, Donna M.
    CANCER, 2010, 116 (16) : 3807 - 3814
12345